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AbstrACt
Introduction The benefits and risk of intravenous iron 
have been documented in previous systematic reviews and 
continue to be the subject of randomised controlled trials 
(RCTs). An ongoing issue that continues to be raised is the 
relationship between administering iron and developing 
infection. This is supported by biological plausibility from 
animal models. We propose an update of a previously 
published systematic review and meta-analysis with the 
primary focus being infection.
Methods and analysis We will include RCTs and 
non-randomised studies (NRS) in this review update. 
We will search the relevant electronic databases. Two 
reviewers will independently extract data. Risk of bias 
for RCTs and NRS will be assessed using the relevant 
tools recommended by The Cochrane Collaboration. 
Data extracted from RCTs and NRS will be analysed 
and reported separately. Pooled data from RCTs will 
be analysed using a random effects model. We will 
also conduct subgroup analyses to identify any patient 
populations that may be at increased risk of developing 
infection. We will provide a narrative synthesis on the 
definitions, sources and responsible pathogens for 
infection in the included studies. Overall quality of 
evidence on the safety outcomes of mortality and infection 
will be assessed using the Grading of Recommendations, 
Assessment, Development and Evaluation approach.
Ethics and dissemination This systematic review will 
only investigate published studies and therefore ethical 
approval is not required. The results will be broadly 
distributed through conference presentations and peer-
reviewed publications.
trial registration number PROSPERO 
(CRD42018096023).
IntroduCtIon
Treating anaemia is a key pillar of patient 
blood management and a recent James Lind 
prioritisation exercise ranked the timely iden-
tification of anaemia and treatment as a top 
10 priority for research into blood transfusion 
and blood donation.1 Systematic reviews have 
shown the efficacy of intravenous iron with 
regards to treating anaemia and reducing 
blood transfusion requirements,2 3 although 
with varying degrees of effect size and the 
primary outcomes in majority of trials were 
haematological (change in haemoglobin 
concentration, transfusion requirements) 
instead of clinical outcomes (eg, quality of 
life).
Despite the widespread use of intravenous 
iron,1 2 uncertainty persists as to whether intra-
venous iron is associated with an increased 
risk of infection. The uncertain relationship 
between iron and infection has long been 
postulated and remains a topic of interest 
in ongoing trials of oral iron, for example, 
in the setting of malaria and other tropical 
infections in low-resource country settings.4 
Iron is essential for extracellular pathogens 
as it an ideal redox catalyst for important 
cellular processes such as respiration and 
DNA replication.5 Humans are able to with-
hold free (non-transferrin-bound) iron 
from invading pathogens through a process 
termed nutritional immunity in an effort to 
limit infection.5 6 Intravenous iron adminis-
tration can lead to increased levels of circu-
lating free iron, which can be detrimental to 
the host and promote pathogen growth. Such 
strengths and limitations of this study
 ► Systematic review protocol primarily focusing on a 
safety outcome (risk of infection) with intravenous 
preparations.
 ► Comprehensive review that will include data from 
randomised controlled trials and non-randomised 
studies.
 ► Infection is not often a predefined endpoint in pub-
lished studies and definitions of infection will vary 
across studies.
 ► There will be considerable heterogeneity in partic-
ipant populations, doses and types of intravenous 
iron used and follow-up time points.
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an interaction is supported by biological plausibility in 
recent animal models where the administration of intra-
venous iron worsening shock, lung injury and mortality.7
Two recent systematic reviews have investigated the effi-
cacy and safety of intravenous iron therapy.2 7 The first 
systematic review identified 72 randomised controlled 
trials (RCTs) that included 10 605 participants. The 
authors reported a reduced risk of requirement for 
red blood cell (RBC) transfusion (risk ratio (RR) 0.74, 
95% CI 0.62 to 0.88; 22 RCTs, 3321 participants). Of note, 
this potential benefit was counterbalanced a significantly 
increased risk of infection (RR 1.34, 95% CI 1.10 to 1.64; 
24 RCTs, 4400 participants) when intravenous iron was 
compared with oral iron or no iron.2 The second system-
atic review pooled data from 32 RCTs and showed a point 
estimate which again favoured infection, although this 
was statistically non-significant (RR 1.17; 95% CI 0.83 
to 1.65).8 Interpreting data on infection from these 
meta-analyses is challenging because infection is not 
always defined as a prespecified, standardised outcome 
measure in RCTs but rather reported as safety outcome. 
A recent editorial highlighted the need for an adequately 
powered trial of intravenous iron with infection as a 
primary outcome.6
Given the ongoing uncertainty regarding the risk of 
infection, the primary objective of this systematic review 
was to update the previous review by Litton et al3 by iden-
tifying and incorporating recent trial data to evaluate the 
safety data for intravenous iron on the risk of infection 
across all clinical settings. A better understanding of the 
characterisation of infection in patients receiving iron 
therapy will help inform the design of subsequent trials 
in particular groups of patients (eg, critically ill, emer-
gency surgery) in whom the risk of infection is of clin-
ical concern. Our secondary objective is to continue to 
collect efficacy data to focusing primarily on changes in 
haemoglobin concentration, transfusion requirements 
and functional outcomes.
MEthods
We used the Preferred Reporting Items for Systematic 
Review and Meta-Analysis (PRISMA) Protocols reporting 
guidelines.9 Studies will be selected according to the 
criteria outlined below.
Eligibility criteria
We will include RCTs from 1 January 2013 onwards as the 
last search date for the previous review was June 2013.2 We 
will also include non-randomised studies (NRS) in this 
updated review as infection may not always be reported in 
RCTs and the findings of infection outcomes reported in 
NRS may be useful to inform the design of a future RCT. 
We will only include NRS that meet the following criteria:
 ► Published since 1 January 2007 as this is the year from 
which newer intravenous iron preparations (Ferin-
ject, Monofer, Venofer, Injectofer) received and/or 
renewed their marketing authorisation. Therefore, 
any data extracted is likely to be reflective of current 
practice. Studies evaluating low molecular weight 
dextran (INFed, Cosmofer), ferumoxytol, ferric 
pyrophosphate citrate (TriFeric) and iron polymaltose 
will also be included.
 ► At least two comparable groups (including controlled 
before and after, and prospective/retrospective 
cohort studies).
 ► Quasi-RCTs.
 ► Provide data on our primary outcome of infection.
We will exclude any studies that provide no outcome 
data of interest, NRS published before 1 January 2007 
and NRS that do not have an intravenous iron compar-
ison arm. We will include studies examining all partici-
pant populations (including paediatrics, pregnancy) but 
excluding healthy volunteers. Included studies would 
compare intravenous iron to no iron/placebo or oral 
iron.
Our primary outcome of interest is the number of 
patients who develop an infection as defined by the 
study authors. Secondary safety and efficacy outcomes 
include:
 ► Mortality—short-term (≤30 days), long-term 
(>30 days).
 ► Hospital length of stay.
 ► Change in haemoglobin concentration from base-
line/pretreatment levels to end of study period.
 ► Transfusion requirements during study period (% 
transfused, mean number of RBC units transfused).
Information sources and search strategy
We will search the following databases for RCTs (from 
1 January 2013), systematic reviews and NRS (from 
1 January 2007)—Cochrane Central Register for 
Controlled Trials; Medline (Ovid interface); Ovid Inter-
face; Cumulative Index to Nursing and Allied Health 
Literature (CINAHL); Transfusion Evidence Library; 
Web of Science Conference Proceedings Citation Index 
Science. This will be supplemented by searching ongoing 
trial databases such as  ClinicalTrials. gov and WHO Inter-
national Clinical Trials Search Registry Platform. Citation 
lists of included studies and relevant reviews will also be 
scanned to identify any studies missed by the search. A 
draft Medline search strategy is included in online supple-
mentary appendix 1.
study selection
Literature search results will be uploaded to Covidence, 
a web-based software platform, to facilitate citation 
screening between reviewers. Review authors will inde-
pendently screen the titles and abstracts yielded by the 
search against the prespecified inclusion criteria. Two 
review authors will then independently screen the full-
text reports and decide whether these meet the inclusion 
criteria. Disagreements will be resolved through discus-
sion, and if necessary, referred to a third reviewer. The 
study selection process will be reported in a PRISMA flow 
diagram.
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data extraction
For RCTs, two reviewers will use the data extraction form 
used for the original review to extract data independently. 
We will standardise and pilot a data extraction form for 
NRS and items for extraction from NRS will include:
 ► Data on confounding factors.
 ► Comparability of groups based on the consideration 
of confounding factors.
 ► Methods used to control for confounding.
 ► Effect estimates—both adjusted and unadjusted if 
available.
For both sets of studies, we will extract the following 
additional data, if reported, on the outcome of infection:
 ► Definition of infection used (ie, guideline based, labo-
ratory based, clinical discretion).
 ► Site of infection (eg, lung, wound, gastrointestinal).
 ► Reporting of identified pathogens.
 ► Antibiotic usage.
Disagreements will be resolved through discussion, and 
if necessary, referred to a third reviewer. We will contact 
study authors to resolve any uncertainties.
risk-of-bias assessment
Risk of bias for the RCTs will be reported using the 
Cochrane Risk of Bias tool.10 For the non-RCT data, risk 
of bias will be reported using the Risk of Bias in Non-Ran-
domized Studies - of Interventions (ROBINS-I) developed 
by the Cochrane Bias Methods Group.11 Two reviewers 
will make these judgements independently.
data synthesis
Data from RCTs and NRS will be analysed and reported 
separately.
RCTs
The primary endpoint will be the proportion of partici-
pants who developed an infection. Dichotomous outcomes 
(infection, mortality, requirement for blood transfu-
sion) will be reported as RRs with corresponding 95% 
CIs. Continuous outcomes will be reported as weighted 
mean (with 95% CI) or standardised mean differences 
(95% CI) as appropriate. For continuous measures, the 
mean difference in change from baseline values between 
groups will be used preferentially; if change from base-
line values is not reported, then the mean difference in 
measures at follow-up will be used. The unit of analysis 
will be per individual randomised. Data from included 
studies will be pooled for meta-analysis using a random 
effects model. Statistical heterogeneity will be tested using 
the I2 statistic and I2>50% will be considered as substan-
tial heterogeneity. If substantial heterogeneity is present 
among the trials, the study characteristics of the included 
studies will be analysed and we will attempt to explain the 
heterogeneity by subgroup analysis or sensitivity analysis. 
If sufficient data are available, we will undertake metare-
gression to examine the effect of cumulative intravenous 
iron dose and the incidence of infection in the control 
group (as a surrogate for background/endemic burden 
of infection) on our primary outcome. Statistical analysis 
will be conducted on RevMan V.5.1. and STATA (V.14, 
StataCorp LP, College Station, Texas, USA).
NRS
For NRS, we will only report results descriptively on the 
primary outcome of infection instead of pooling results 
due to heterogeneity in clinical conditions, study designs 
and variations in statistical adjustment. If possible, results 
will be displayed in a forest plot, with studies sorted 
according to study design features, and the pooled esti-
mate will be suppressed as recommended by the Cochrane 
Collaboration.6
Analysis of subgroups
Subgroup analysis of the primary safety outcome (infec-
tion) will be performed on the following:
 ► Clinical settings (in-patient medical (any), outpatient 
(any), elective surgical, non-elective (urgent/emer-
gency) surgical, obstetrics, paediatrics, critically ill).
 ► Different iron profiles at enrolment as defined by the 
study authors (true iron deficiency, functional iron 
deficiency, iron-restricted erythropoiesis).
 ► Mode of administration (eg, single dose, continuous 
infusion, multiple boluses).
 ► Cumulative dose of intravenous iron.
 ► Incidence of infection in the control group.
We will carry out a sensitivity analysis on infection and 
mortality outcomes by excluding studies with a high risk 
of bias. We will assess for publication bias on the primary 
outcome with a funnel plot if ≥10 studies are available, 
plotting the OR for proportion that develop infection 
against the SE of the log OR.
A systematic narrative synthesis will be provided with 
information presented in the text and tables to summarise 
data on infection provided in the include studies. This 
narrative synthesis will explore the definitions of infec-
tion used, reporting of infection source and pathogens 
and antibiotic use.
Confidence in cumulative evidence
According to the Grading of Recommendations, Assess-
ment, Development and Evaluation (GRADE) approach, 
we will assess the overall quality of evidence for the main 
safety outcomes of infection and mortality.12 In line with 
current GRADE guidance, if the certainty of evidence 
differs between RCTs and NRS, we will present summary 
of findings tables for the higher certainty of evidence. 
If the certainty ratings are the same, results from both 
bodies will be presented separately.13
Patient and public involvement
Patients and members of the public were not directly 
involved in the design of this study. However, appropriate 
management of anaemia, through interventions such 
as iron therapy, has been identified as a key research 
priority in a recent James Lind Priority Setting Partner-
ship exercise.1
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dIsCussIon
Recent patient blood management efforts have attempted 
to reduce blood transfusion by using alternative therapies 
such as intravenous iron. Safety concerns surrounding 
older preparations, mainly anaphylaxis, have been allayed 
by the development of newer, stable preparations which 
has led to intravenous iron being used more frequently in 
multiple settings.14 Despite its widespread use, concerns 
surrounding infection remain both from systematic 
reviews and animal models.
Our review will provide an up to date and comprehen-
sive estimate of the risk of infection associated with intra-
venous iron preparations across multiple patient groups. 
In addition, we will also provide data on the characterisa-
tion of infection as a step towards standardising infection 
as an outcome measure for future trials of intravenous 
iron.
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